Found 1727 clinical trials
Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA
This clinical trial is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (Otaplimastat) and recombinant tissue Plasminogen Activator (rtPA) standard of care. In this clinical trial, rtPA will be injected intravenously using an infusion device. If reperfusion is not occur in spite of rtPA therapy, …
- 0 views
- 19 Feb, 2024
- 1 location
Pectin Use in Pediatric Intestinal Rehabilitation
Pediatric short bowel patients, age 6 months to 21 years old, followed in our intestinal rehabilitation clinic, will be screened for qualification in the study. If meets qualification, will be consented for the study. The study involves patients receiving green beans in their diet for three months with data collection …
- 0 views
- 19 Feb, 2024
- 1 location
Cerebellar tDCS in Children With Autism Spectrum Disorder
The purpose of this research study is to investigate whether tDCS to the cerebellum (specifically, the right crus I/II area of the cerebellum) of children and young adults with autism spectrum disorders (ASD) is safe and to examine its effects on some of the symptoms of ASD, such as repetitive …
- 0 views
- 19 Feb, 2024
- 2 locations
The Influence of a Perturbation Training on Balance Recovery of Old Adults: a Randomized Controlled Trial
Falls are major contributors for immobility and independency. Most falls in older adults occur during walking after a sudden unexpected loss of balance. It was well-established that balance can be improved by performance of a training program that provides perturbation (unexpected perturbations of balance). The main aim of the current …
- 0 views
- 19 Feb, 2024
- 3 locations
Upper Limb Loss Perturbation Response
Recent investigations have suggested that persons with upper limb loss experience a high prevalence of falls with a quarter of reported falls resulting from a trip. Moreover, studies indicate that missing part of an arm may negatively impact balance and that use of a prosthesis exacerbates this problem. While the …
- 0 views
- 19 Feb, 2024
- 1 location
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.
- 0 views
- 19 Feb, 2024
- 4 locations
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.
Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac …
- 0 views
- 24 Nov, 2025
- 1 location
Venetoclax SL-401 and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant protein consisting of IL-3 linked to a …
- 0 views
- 19 Feb, 2024
- 1 location
Improving Uptake of Genetic Cancer Risk Assessment in African American Women- Video
Genetic counseling and testing (GCT) provides invaluable information for women who are at-risk of hereditary breast and/or ovarian cancer (HBOC). Black women underutilize GCT compared to White women. This study will conduct a RCT to test the efficacy of a culturally-tailored theory-based video intervention aimed to address key psychosocial factors …
- 0 views
- 19 Feb, 2024
- 1 location
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.
- 0 views
- 19 Feb, 2024
- 1 location